Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress

<p>– ENLIVEN results demonstrated that treatment with pegozafermin 30mg weekly and 44mg every-two-week doses resulted in statistically significant changes on both primary histology endpoints – – New data showed pegozafermin resulted in significant benefit across several key sub populations of NASH patients, and that adding pegozafermin to patients taking GLP-1 therapies improved key NASH measures […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/data-from-89bios-enliven-phase-2b-trial-of-pegozafermin-in-patients-with-nonalcoholic-steatohepatitis-nash-published-in-the-new-england-journal-of-medicine-and-simultaneously-presented-in-a/">Data from 89bio’s ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) Published in The New England Journal of Medicine and Simultaneously Presented in a Late-breaker Session at the EASL International Liver Congress</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>